Lilly's Lechleiter eliminates manufacturing posts

Share this article:
Lilly CEO John Lechleiter
Lilly CEO John Lechleiter
In his first major move as CEO, Eli Lilly's John Lechleiter today announced plans to cut 500 manufacturing jobs at sites near the company's Indianapolis headquarters.

The manufacturing sites focused on production of ingredients for insulin products Humulin and Humalog and osteoporosis treatment Forteo. While most of the cuts are planned for manufacturing, some will come from R&D, Lilly said.

“For several years we have focused on strategic efforts to lower costs, increase flexibility and improve productivity across the business,” Lechleiter said in a statement. “This strategy calls for reducing investments in some areas while increasing investments in others, and the streamlining decisions announced today are an example of this.”

Lechlieter stepped into the CEO role at Lilly on April 1, replacing Sidney Taurel who retired at the end of March.

Lilly has cut its global employment, mostly through attrition, by about 12% since the middle of 2004 and now has approximately 5,500 workers.

The job cuts follow Lilly's decision last month to scrap development of its inhaled insulin device dubbed AIR. 

A late-stage trial of AIR was slated to wrap in time for NDA submission of the product in 2009.

Share this article:

Next Article in News

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.